100 related articles for article (PubMed ID: 22658344)
21. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
Chen P; Li J; Ge LP; Dai CH; Li XQ
Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
[TBL] [Abstract][Full Text] [Related]
23. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
Ikeda S; Takabe K; Suzuki K
Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
25. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
26. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
27. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
29. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
30. Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer.
Sun HB; Zheng Y; Ou W; Fang Q; Li P; Ye X; Zhang BB; Yang H; Wang SY
Ann Thorac Surg; 2011 May; 91(5):1562-7. PubMed ID: 21524465
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
32. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer.
Skjefstad K; Grindstad T; Khanehkenari MR; Richardsen E; Donnem T; Kilvaer T; Andersen S; Bremnes RM; Busund LT; Al-Saad S
Steroids; 2016 Sep; 113():5-13. PubMed ID: 27234503
[TBL] [Abstract][Full Text] [Related]
35. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome.
Stabile LP; Dacic S; Land SR; Lenzner DE; Dhir R; Acquafondata M; Landreneau RJ; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jan; 17(1):154-64. PubMed ID: 21062926
[TBL] [Abstract][Full Text] [Related]
36. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).
Cheng TD; Darke AK; Redman MW; Zirpoli GR; Davis W; Payne Ondracek R; Bshara W; Omilian AR; Kratzke R; Reid ME; Molina JR; Kolesar JM; Chen Y; MacRae RM; Moon J; Mack P; Gandara DR; Kelly K; Santella RM; Albain KS; Ambrosone CB
J Natl Cancer Inst; 2018 Jul; 110(7):734-742. PubMed ID: 29346580
[TBL] [Abstract][Full Text] [Related]
37. Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression.
Li CY; Ren YJ; Li YD
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27420968
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.
Scambia G; Benedetti-Panici P; Ferrandina G; Distefano M; Salerno G; Romanini ME; Fagotti A; Mancuso S
Br J Cancer; 1995 Aug; 72(2):361-6. PubMed ID: 7640219
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
40. Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer.
Deng F; Li M; Shan WL; Qian LT; Meng SP; Zhang XL; Wang BL
Oncol Lett; 2017 Apr; 13(4):2359-2365. PubMed ID: 28454404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
